Several analysts have recently updated their ratings and price targets for Pfizer (NYSE: PFE):
- 11/14/2026 – Pfizer was upgraded by Wall Street Zen from “hold” to “buy”.
- 11/12/2026 – Pfizer had its “market perform” rating reaffirmed by Sanford C. Bernstein. They now have a $29.00 price target on the stock.
- 11/9/2026 – Pfizer was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
- 11/6/2026 – Pfizer was given a new $34.00 price target by FBN Securities.
- 11/6/2026 – Pfizer had its price target raised by Freedom Broker from $33.00 to $34.00. They now have a “buy” rating on the stock.
- 11/6/2026 – Pfizer was downgraded by DZ Bank from “buy” to “hold”.
- 11/5/2026 – Pfizer had its price target raised by Guggenheim from $31.00 to $33.00. They now have a “buy” rating on the stock.
- 11/4/2026 – Pfizer was given a new $40.00 price target by Argus.
- 11/4/2026 – Pfizer had its price target raised by UBS Group from $27.00 to $30.00. They now have a “neutral” rating on the stock.
- 11/4/2026 – Pfizer had its price target raised by Scotiabank from $33.00 to $35.00. They now have a “sector outperform” rating on the stock.
- 11/4/2026 – Pfizer had its price target raised by Citigroup from $27.00 to $30.00. They now have a “neutral” rating on the stock.
- 11/4/2026 – Pfizer had its price target raised by Royal Bank Of Canada from $25.00 to $28.00. They now have a “sector perform” rating on the stock.
- 10/13/2026 – Pfizer had its “buy” rating reaffirmed by Guggenheim.
- 10/10/2026 – Pfizer was downgraded by Wall Street Zen from “buy” to “hold”.
- 10/9/2026 – Pfizer had its price target raised by JPMorgan Chase & Co. from $28.00 to $30.00. They now have a “neutral” rating on the stock.
- 10/8/2026 – Pfizer had its price target raised by Cantor Fitzgerald from $27.00 to $28.00. They now have a “neutral” rating on the stock.
- 10/6/2026 – Pfizer had its price target raised by Scotiabank from $30.00 to $33.00. They now have an “outperform” rating on the stock.
Pfizer Price Performance
Shares of NYSE:PFE opened at $28.41 on Wednesday. The firm has a market capitalization of $161.90 billion, a price-to-earnings ratio of 40.58, a price-to-earnings-growth ratio of 1.90 and a beta of 0.31. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.42 and a quick ratio of 1.10. The business’s 50 day simple moving average is $28.82 and its 200-day simple moving average is $27.01. Pfizer Inc. has a 12 month low of $23.62 and a 12 month high of $31.44.
Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.13. The firm had revenue of $16.58 billion during the quarter, compared to the consensus estimate of $15.85 billion. Pfizer had a return on equity of 19.88% and a net margin of 6.34%. Pfizer’s quarterly revenue was down .4% on a year-over-year basis. During the same period last year, the business posted $0.87 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 3.04 earnings per share for the current fiscal year.
Pfizer Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio is presently 245.71%.
Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.
Read More
- Five stocks we like better than Pfizer
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Pfizer Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc and related companies with MarketBeat.com's FREE daily email newsletter.
